Risks Still Elevated At These Prices As ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Dive 30%

Simply Wall StMar 16 09:44 ET

ProQR Therapeutics Price Target Maintained With a $4.00/Share by Chardan Capital

Dow JonesMar 14 08:39 ET · Ratings

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMar 14 08:39 ET · Ratings

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12

BenzingaMar 14 08:19 ET · Ratings

Express News | ProQR Therapeutics NV Files for Shelf of up to up to 3.5 Mln Ordinary Shares by Selling Stockholder - SEC Filing

ReutersMar 13 08:31 ET

ProQR Therapeutics Reports FY24 EPS (EUR 0.32) Vs (EUR 0.35) Last Year

TipRanksMar 13 07:22 ET